aluates Reports

$ 0.0

Automative

Antivenom- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031

Published Date: August 2025

Report Code: QYRE-Auto-19N8983

BUY CHAPTERS

Antivenom- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031

Code: QYRE-Auto-19N8983

Report

August 2025

Pages:126

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Haffkine Bio Pharmaceutical

Rare Disease Therapeutics

Flynn Pharma

Vins Bioproducts

Bharat Serums and Vaccines

Serum Biotech

MicroPharm

CSL Limited

Pfizer Inc

Merck

BTG Plc

Antivenom- Market Size

The global market for Antivenom was estimated to be worth US$ 1041 million in 2024 and is forecast to a readjusted size of US$ 1383 million by 2031 with a CAGR of 4.2% during the forecast period 2025-2031.

Antivenom- Market

Antivenom, also known as antivenin, venom antiserum and antivenom immunoglobulin, is a medication made from antibodies which is used to treat certain venomous bites and stings. They are only recommended if there is significant toxicity or a high risk of toxicity. The specific antivenom needed depends on the species involved. It is given by injection.

CSL is the world leading manufacturer in global Anti-Venom market with the market share of 27%, in terms of revenue, followed by Merck, BTG, Pfizer, Haffkine Bio-Pharmaceutical, Rare Disease Therapeutics, Flynn Pharma, Vins Bioproducts, Bharat Serums and Vaccines, Serum Biotech and MicroPharm. These 11 companies accounted for 68% of the revenue market share in 2019. Asia-Pacific, Middle East and Africa are the largest consumption regions, occupied about 77% of market share, in terms of volume. The application of Anti-Venom in hospital and clinics take the main global shares. The polyvalent Anti-Venom takes more global revenue shares compared to the Monovalent Anti-Venom, which accounts for 67% in 2019.

This report aims to provide a comprehensive presentation of the global market for Antivenom, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Antivenom by region & country, by Type, and by Application.

The Antivenom market size, estimations, and forecasts are provided in terms of sales volume (K Vials) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antivenom.

Market Segmentation

Scope of Antivenom- Market Report

Report Metric	Details
Report Name	Antivenom- Market
Forecasted market size in 2031	US$ 1383 million
CAGR	4.2%
Forecasted years	2025 - 2031
Segment by Type	Polyvalent antivenom Monovalent antivenom
Segment by Application	Non-profit Institutions Hospitals and Clinic
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	CSL, Merck, BTG, Pfizer, Haffkine Bio-Pharmaceutical, Rare Disease Therapeutics, Flynn Pharma, Vins Bioproducts, Bharat Serums and Vaccines, Serum Biotech, MicroPharm
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Antivenom manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Antivenom in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Antivenom in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

FAQ for this report

What is the Antivenom- Market size in 2031?

Ans: The Antivenom- Market size in 2031 will be US$ 1383 million.

What is the CSL, Merck, BTG, Pfizer, Haffkine Bio Pharmaceutical, Rare Disease Therapeutics, Flynn Pharma, Vins Bioproducts, Bharat Serums and Vaccines, Serum Biotech, MicroPharm share in Antivenom- Market?

Ans: CSL is the world leading manufacturer in global Anti-Venom market with the market share of 27%, in terms of revenue, followed by Merck, BTG, Pfizer, Haffkine Bio-Pharmaceutical, Rare Disease Therapeutics, Flynn Pharma, Vins Bioproducts, Bharat Serums and Vaccines, Serum Biotech and MicroPharm.

What is the Antivenom- Market share by region?

Ans: Asia-Pacific, Middle East and Africa are the largest consumption regions, occupied about 77% of market share, in terms of volume.

Who are the main players in the Antivenom- Market report?

Ans: The main players in the Antivenom- Market are CSL, Merck, BTG, Pfizer, Haffkine Bio-Pharmaceutical, Rare Disease Therapeutics, Flynn Pharma, Vins Bioproducts, Bharat Serums and Vaccines, Serum Biotech, MicroPharm

What are the Application segmentation covered in the Antivenom- Market report?

Ans: The Applications covered in the Antivenom- Market report are Non-profit Institutions, Hospitals and Clinic

What are the Type segmentation covered in the Antivenom- Market report?

Ans: The Types covered in the Antivenom- Market report are Polyvalent antivenom, Monovalent antivenom

Recommended Reports

Antivenom & Antibodies

Immunoglobulins & Sera

Anti-infective Therapeutics

1 Market Overview

1.1 Antivenom Product Introduction

1.2 Global Antivenom Market Size Forecast

1.2.1 Global Antivenom Sales Value (2020-2031)

1.2.2 Global Antivenom Sales Volume (2020-2031)

1.2.3 Global Antivenom Sales Price (2020-2031)

1.3 Antivenom Market Trends & Drivers

1.3.1 Antivenom Industry Trends

1.3.2 Antivenom Market Drivers & Opportunity

1.3.3 Antivenom Market Challenges

1.3.4 Antivenom Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global Antivenom Players Revenue Ranking (2024)

2.2 Global Antivenom Revenue by Company (2020-2025)

2.3 Global Antivenom Players Sales Volume Ranking (2024)

2.4 Global Antivenom Sales Volume by Company Players (2020-2025)

2.5 Global Antivenom Average Price by Company (2020-2025)

2.6 Key Manufacturers Antivenom Manufacturing Base and Headquarters

2.7 Key Manufacturers Antivenom Product Offered

2.8 Key Manufacturers Time to Begin Mass Production of Antivenom

2.9 Antivenom Market Competitive Analysis

2.9.1 Antivenom Market Concentration Rate (2020-2025)

2.9.2 Global 5 and 10 Largest Manufacturers by Antivenom Revenue in 2024

2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antivenom as of 2024)

2.10 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 Polyvalent antivenom

3.1.2 Monovalent antivenom

3.2 Global Antivenom Sales Value by Type

3.2.1 Global Antivenom Sales Value by Type (2020 VS 2024 VS 2031)

3.2.2 Global Antivenom Sales Value, by Type (2020-2031)

3.2.3 Global Antivenom Sales Value, by Type (%) (2020-2031)

3.3 Global Antivenom Sales Volume by Type

3.3.1 Global Antivenom Sales Volume by Type (2020 VS 2024 VS 2031)

3.3.2 Global Antivenom Sales Volume, by Type (2020-2031)

3.3.3 Global Antivenom Sales Volume, by Type (%) (2020-2031)

3.4 Global Antivenom Average Price by Type (2020-2031)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Non-profit Institutions

4.1.2 Hospitals and Clinic

4.2 Global Antivenom Sales Value by Application

4.2.1 Global Antivenom Sales Value by Application (2020 VS 2024 VS 2031)

4.2.2 Global Antivenom Sales Value, by Application (2020-2031)

4.2.3 Global Antivenom Sales Value, by Application (%) (2020-2031)

4.3 Global Antivenom Sales Volume by Application

4.3.1 Global Antivenom Sales Volume by Application (2020 VS 2024 VS 2031)

4.3.2 Global Antivenom Sales Volume, by Application (2020-2031)

4.3.3 Global Antivenom Sales Volume, by Application (%) (2020-2031)

4.4 Global Antivenom Average Price by Application (2020-2031)

5 Segmentation by Region

5.1 Global Antivenom Sales Value by Region

5.1.1 Global Antivenom Sales Value by Region: 2020 VS 2024 VS 2031

5.1.2 Global Antivenom Sales Value by Region (2020-2025)

5.1.3 Global Antivenom Sales Value by Region (2026-2031)

5.1.4 Global Antivenom Sales Value by Region (%), (2020-2031)

5.2 Global Antivenom Sales Volume by Region

5.2.1 Global Antivenom Sales Volume by Region: 2020 VS 2024 VS 2031

5.2.2 Global Antivenom Sales Volume by Region (2020-2025)

5.2.3 Global Antivenom Sales Volume by Region (2026-2031)

5.2.4 Global Antivenom Sales Volume by Region (%), (2020-2031)

5.3 Global Antivenom Average Price by Region (2020-2031)

5.4 North America

5.4.1 North America Antivenom Sales Value, 2020-2031

5.4.2 North America Antivenom Sales Value by Country (%), 2024 VS 2031

5.5 Europe

5.5.1 Europe Antivenom Sales Value, 2020-2031

5.5.2 Europe Antivenom Sales Value by Country (%), 2024 VS 2031

5.6 Asia Pacific

5.6.1 Asia Pacific Antivenom Sales Value, 2020-2031

5.6.2 Asia Pacific Antivenom Sales Value by Region (%), 2024 VS 2031

5.7 South America

5.7.1 South America Antivenom Sales Value, 2020-2031

5.7.2 South America Antivenom Sales Value by Country (%), 2024 VS 2031

5.8 Middle East & Africa

5.8.1 Middle East & Africa Antivenom Sales Value, 2020-2031

5.8.2 Middle East & Africa Antivenom Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions Antivenom Sales Value Growth Trends, 2020 VS 2024 VS 2031

6.2 Key Countries/Regions Antivenom Sales Value

6.2.1 Key Countries/Regions Antivenom Sales Value, 2020-2031

6.2.2 Key Countries/Regions Antivenom Sales Volume, 2020-2031

6.3 United States

6.3.1 United States Antivenom Sales Value, 2020-2031

6.3.2 United States Antivenom Sales Value by Type (%), 2024 VS 2031

6.3.3 United States Antivenom Sales Value by Application, 2024 VS 2031

6.4 Europe

6.4.1 Europe Antivenom Sales Value, 2020-2031

6.4.2 Europe Antivenom Sales Value by Type (%), 2024 VS 2031

6.4.3 Europe Antivenom Sales Value by Application, 2024 VS 2031

6.5 China

6.5.1 China Antivenom Sales Value, 2020-2031

6.5.2 China Antivenom Sales Value by Type (%), 2024 VS 2031

6.5.3 China Antivenom Sales Value by Application, 2024 VS 2031

6.6 Japan

6.6.1 Japan Antivenom Sales Value, 2020-2031

6.6.2 Japan Antivenom Sales Value by Type (%), 2024 VS 2031

6.6.3 Japan Antivenom Sales Value by Application, 2024 VS 2031

6.7 South Korea

6.7.1 South Korea Antivenom Sales Value, 2020-2031

6.7.2 South Korea Antivenom Sales Value by Type (%), 2024 VS 2031

6.7.3 South Korea Antivenom Sales Value by Application, 2024 VS 2031

6.8 Southeast Asia

6.8.1 Southeast Asia Antivenom Sales Value, 2020-2031

6.8.2 Southeast Asia Antivenom Sales Value by Type (%), 2024 VS 2031

6.8.3 Southeast Asia Antivenom Sales Value by Application, 2024 VS 2031

6.9 India

6.9.1 India Antivenom Sales Value, 2020-2031

6.9.2 India Antivenom Sales Value by Type (%), 2024 VS 2031

6.9.3 India Antivenom Sales Value by Application, 2024 VS 2031

7 Company Profiles

7.1 CSL

7.1.1 CSL Company Information

7.1.2 CSL Introduction and Business Overview

7.1.3 CSL Antivenom Sales, Revenue, Price and Gross Margin (2020-2025)

7.1.4 CSL Antivenom Product Offerings

7.1.5 CSL Recent Development

7.2 Merck

7.2.1 Merck Company Information

7.2.2 Merck Introduction and Business Overview

7.2.3 Merck Antivenom Sales, Revenue, Price and Gross Margin (2020-2025)

7.2.4 Merck Antivenom Product Offerings

7.2.5 Merck Recent Development

7.3 BTG

7.3.1 BTG Company Information

7.3.2 BTG Introduction and Business Overview

7.3.3 BTG Antivenom Sales, Revenue, Price and Gross Margin (2020-2025)

7.3.4 BTG Antivenom Product Offerings

7.3.5 BTG Recent Development

7.4 Pfizer

7.4.1 Pfizer Company Information

7.4.2 Pfizer Introduction and Business Overview

7.4.3 Pfizer Antivenom Sales, Revenue, Price and Gross Margin (2020-2025)

7.4.4 Pfizer Antivenom Product Offerings

7.4.5 Pfizer Recent Development

7.5 Haffkine Bio-Pharmaceutical

7.5.1 Haffkine Bio-Pharmaceutical Company Information

7.5.2 Haffkine Bio-Pharmaceutical Introduction and Business Overview

7.5.3 Haffkine Bio-Pharmaceutical Antivenom Sales, Revenue, Price and Gross Margin (2020-2025)

7.5.4 Haffkine Bio-Pharmaceutical Antivenom Product Offerings

7.5.5 Haffkine Bio-Pharmaceutical Recent Development

7.6 Rare Disease Therapeutics

7.6.1 Rare Disease Therapeutics Company Information

7.6.2 Rare Disease Therapeutics Introduction and Business Overview

7.6.3 Rare Disease Therapeutics Antivenom Sales, Revenue, Price and Gross Margin (2020-2025)

7.6.4 Rare Disease Therapeutics Antivenom Product Offerings

7.6.5 Rare Disease Therapeutics Recent Development

7.7 Flynn Pharma

7.7.1 Flynn Pharma Company Information

7.7.2 Flynn Pharma Introduction and Business Overview

7.7.3 Flynn Pharma Antivenom Sales, Revenue, Price and Gross Margin (2020-2025)

7.7.4 Flynn Pharma Antivenom Product Offerings

7.7.5 Flynn Pharma Recent Development

7.8 Vins Bioproducts

7.8.1 Vins Bioproducts Company Information

7.8.2 Vins Bioproducts Introduction and Business Overview

7.8.3 Vins Bioproducts Antivenom Sales, Revenue, Price and Gross Margin (2020-2025)

7.8.4 Vins Bioproducts Antivenom Product Offerings

7.8.5 Vins Bioproducts Recent Development

7.9 Bharat Serums and Vaccines

7.9.1 Bharat Serums and Vaccines Company Information

7.9.2 Bharat Serums and Vaccines Introduction and Business Overview

7.9.3 Bharat Serums and Vaccines Antivenom Sales, Revenue, Price and Gross Margin (2020-2025)

7.9.4 Bharat Serums and Vaccines Antivenom Product Offerings

7.9.5 Bharat Serums and Vaccines Recent Development

7.10 Serum Biotech

7.10.1 Serum Biotech Company Information

7.10.2 Serum Biotech Introduction and Business Overview

7.10.3 Serum Biotech Antivenom Sales, Revenue, Price and Gross Margin (2020-2025)

7.10.4 Serum Biotech Antivenom Product Offerings

7.10.5 Serum Biotech Recent Development

7.11 MicroPharm

7.11.1 MicroPharm Company Information

7.11.2 MicroPharm Introduction and Business Overview

7.11.3 MicroPharm Antivenom Sales, Revenue, Price and Gross Margin (2020-2025)

7.11.4 MicroPharm Antivenom Product Offerings

7.11.5 MicroPharm Recent Development

8 Industry Chain Analysis

8.1 Antivenom Industrial Chain

8.2 Antivenom Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 Antivenom Sales Model

8.5.2 Sales Channel

8.5.3 Antivenom Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.1.1 Research Programs/Design

10.1.1.2 Market Size Estimation

10.1.1.3 Market Breakdown and Data Triangulation

10.1.2 Data Source

10.1.2.1 Secondary Sources

10.1.2.2 Primary Sources

10.2 Author Details

10.3 Disclaimer

FEATURED COMPANIES

Haffkine Bio Pharmaceutical

Rare Disease Therapeutics

Flynn Pharma

Vins Bioproducts

Bharat Serums and Vaccines

Serum Biotech

MicroPharm

CSL Limited

Pfizer Inc

Merck

BTG Plc

List of Tables

Table 1. Antivenom Market Trends

Table 2. Antivenom Market Drivers & Opportunity

Table 3. Antivenom Market Challenges

Table 4. Antivenom Market Restraints

Table 5. Global Antivenom Revenue by Company (2020-2025) & (US$ Million)

Table 6. Global Antivenom Revenue Market Share by Company (2020-2025)

Table 7. Global Antivenom Sales Volume by Company (2020-2025) & (K Vials)

Table 8. Global Antivenom Sales Volume Market Share by Company (2020-2025)

Table 9. Global Market Antivenom Price by Company (2020-2025) & (USD/Vial)

Table 10. Key Manufacturers Antivenom Manufacturing Base and Headquarters

Table 11. Key Manufacturers Antivenom Product Type

Table 12. Key Manufacturers Time to Begin Mass Production of Antivenom

Table 13. Global Antivenom Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antivenom as of 2024)

Table 15. Mergers & Acquisitions, Expansion Plans

Table 16. Global Antivenom Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)

Table 17. Global Antivenom Sales Value by Type (2020-2025) & (US$ Million)

Table 18. Global Antivenom Sales Value by Type (2026-2031) & (US$ Million)

Table 19. Global Antivenom Sales Market Share in Value by Type (2020-2025)

Table 20. Global Antivenom Sales Market Share in Value by Type (2026-2031)

Table 21. Global Antivenom Sales Volume by Type: 2020 VS 2024 VS 2031 (K Vials)

Table 22. Global Antivenom Sales Volume by Type (2020-2025) & (K Vials)

Table 23. Global Antivenom Sales Volume by Type (2026-2031) & (K Vials)

Table 24. Global Antivenom Sales Market Share in Volume by Type (2020-2025)

Table 25. Global Antivenom Sales Market Share in Volume by Type (2026-2031)

Table 26. Global Antivenom Price by Type (2020-2025) & (USD/Vial)

Table 27. Global Antivenom Price by Type (2026-2031) & (USD/Vial)

Table 28. Global Antivenom Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)

Table 29. Global Antivenom Sales Value by Application (2020-2025) & (US$ Million)

Table 30. Global Antivenom Sales Value by Application (2026-2031) & (US$ Million)

Table 31. Global Antivenom Sales Market Share in Value by Application (2020-2025)

Table 32. Global Antivenom Sales Market Share in Value by Application (2026-2031)

Table 33. Global Antivenom Sales Volume by Application: 2020 VS 2024 VS 2031 (K Vials)

Table 34. Global Antivenom Sales Volume by Application (2020-2025) & (K Vials)

Table 35. Global Antivenom Sales Volume by Application (2026-2031) & (K Vials)

Table 36. Global Antivenom Sales Market Share in Volume by Application (2020-2025)

Table 37. Global Antivenom Sales Market Share in Volume by Application (2026-2031)

Table 38. Global Antivenom Price by Application (2020-2025) & (USD/Vial)

Table 39. Global Antivenom Price by Application (2026-2031) & (USD/Vial)

Table 40. Global Antivenom Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)

Table 41. Global Antivenom Sales Value by Region (2020-2025) & (US$ Million)

Table 42. Global Antivenom Sales Value by Region (2026-2031) & (US$ Million)

Table 43. Global Antivenom Sales Value by Region (2020-2025) & (%)

Table 44. Global Antivenom Sales Value by Region (2026-2031) & (%)

Table 45. Global Antivenom Sales Volume by Region (K Vials): 2020 VS 2024 VS 2031

Table 46. Global Antivenom Sales Volume by Region (2020-2025) & (K Vials)

Table 47. Global Antivenom Sales Volume by Region (2026-2031) & (K Vials)

Table 48. Global Antivenom Sales Volume by Region (2020-2025) & (%)

Table 49. Global Antivenom Sales Volume by Region (2026-2031) & (%)

Table 50. Global Antivenom Average Price by Region (2020-2025) & (USD/Vial)

Table 51. Global Antivenom Average Price by Region (2026-2031) & (USD/Vial)

Table 52. Key Countries/Regions Antivenom Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031

Table 53. Key Countries/Regions Antivenom Sales Value, (2020-2025) & (US$ Million)

Table 54. Key Countries/Regions Antivenom Sales Value, (2026-2031) & (US$ Million)

Table 55. Key Countries/Regions Antivenom Sales Volume, (2020-2025) & (K Vials)

Table 56. Key Countries/Regions Antivenom Sales Volume, (2026-2031) & (K Vials)

Table 57. CSL Company Information

Table 58. CSL Introduction and Business Overview

Table 59. CSL Antivenom Sales (K Vials), Revenue (US$ Million), Price (USD/Vial) and Gross Margin (2020-2025)

Table 60. CSL Antivenom Product Offerings

Table 61. CSL Recent Development

Table 62. Merck Company Information

Table 63. Merck Introduction and Business Overview

Table 64. Merck Antivenom Sales (K Vials), Revenue (US$ Million), Price (USD/Vial) and Gross Margin (2020-2025)

Table 65. Merck Antivenom Product Offerings

Table 66. Merck Recent Development

Table 67. BTG Company Information

Table 68. BTG Introduction and Business Overview

Table 69. BTG Antivenom Sales (K Vials), Revenue (US$ Million), Price (USD/Vial) and Gross Margin (2020-2025)

Table 70. BTG Antivenom Product Offerings

Table 71. BTG Recent Development

Table 72. Pfizer Company Information

Table 73. Pfizer Introduction and Business Overview

Table 74. Pfizer Antivenom Sales (K Vials), Revenue (US$ Million), Price (USD/Vial) and Gross Margin (2020-2025)

Table 75. Pfizer Antivenom Product Offerings

Table 76. Pfizer Recent Development

Table 77. Haffkine Bio-Pharmaceutical Company Information

Table 78. Haffkine Bio-Pharmaceutical Introduction and Business Overview

Table 79. Haffkine Bio-Pharmaceutical Antivenom Sales (K Vials), Revenue (US$ Million), Price (USD/Vial) and Gross Margin (2020-2025)

Table 80. Haffkine Bio-Pharmaceutical Antivenom Product Offerings

Table 81. Haffkine Bio-Pharmaceutical Recent Development

Table 82. Rare Disease Therapeutics Company Information

Table 83. Rare Disease Therapeutics Introduction and Business Overview

Table 84. Rare Disease Therapeutics Antivenom Sales (K Vials), Revenue (US$ Million), Price (USD/Vial) and Gross Margin (2020-2025)

Table 85. Rare Disease Therapeutics Antivenom Product Offerings

Table 86. Rare Disease Therapeutics Recent Development

Table 87. Flynn Pharma Company Information

Table 88. Flynn Pharma Introduction and Business Overview

Table 89. Flynn Pharma Antivenom Sales (K Vials), Revenue (US$ Million), Price (USD/Vial) and Gross Margin (2020-2025)

Table 90. Flynn Pharma Antivenom Product Offerings

Table 91. Flynn Pharma Recent Development

Table 92. Vins Bioproducts Company Information

Table 93. Vins Bioproducts Introduction and Business Overview

Table 94. Vins Bioproducts Antivenom Sales (K Vials), Revenue (US$ Million), Price (USD/Vial) and Gross Margin (2020-2025)

Table 95. Vins Bioproducts Antivenom Product Offerings

Table 96. Vins Bioproducts Recent Development

Table 97. Bharat Serums and Vaccines Company Information

Table 98. Bharat Serums and Vaccines Introduction and Business Overview

Table 99. Bharat Serums and Vaccines Antivenom Sales (K Vials), Revenue (US$ Million), Price (USD/Vial) and Gross Margin (2020-2025)

Table 100. Bharat Serums and Vaccines Antivenom Product Offerings

Table 101. Bharat Serums and Vaccines Recent Development

Table 102. Serum Biotech Company Information

Table 103. Serum Biotech Introduction and Business Overview

Table 104. Serum Biotech Antivenom Sales (K Vials), Revenue (US$ Million), Price (USD/Vial) and Gross Margin (2020-2025)

Table 105. Serum Biotech Antivenom Product Offerings

Table 106. Serum Biotech Recent Development

Table 107. MicroPharm Company Information

Table 108. MicroPharm Introduction and Business Overview

Table 109. MicroPharm Antivenom Sales (K Vials), Revenue (US$ Million), Price (USD/Vial) and Gross Margin (2020-2025)

Table 110. MicroPharm Antivenom Product Offerings

Table 111. MicroPharm Recent Development

Table 112. Key Raw Materials Lists

Table 113. Raw Materials Key Suppliers Lists

Table 114. Antivenom Downstream Customers

Table 115. Antivenom Distributors List

Table 116. Research Programs/Design for This Report

Table 117. Key Data Information from Secondary Sources

Table 118. Key Data Information from Primary Sources

List of Figures

Figure 1. Antivenom Product Picture

Figure 2. Global Antivenom Sales Value, 2020 VS 2024 VS 2031 (US$ Million)

Figure 3. Global Antivenom Sales Value (2020-2031) & (US$ Million)

Figure 4. Global Antivenom Sales Volume (2020-2031) & (K Vials)

Figure 5. Global Antivenom Sales Price (2020-2031) & (USD/Vial)

Figure 6. Antivenom Report Years Considered

Figure 7. Global Antivenom Players Revenue Ranking (2024) & (US$ Million)

Figure 8. Global Antivenom Players Sales Volume Ranking (2024) & (K Vials)

Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Antivenom Revenue in 2024

Figure 10. Antivenom Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

Figure 11. Polyvalent antivenom Picture

Figure 12. Monovalent antivenom Picture

Figure 13. Global Antivenom Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)

Figure 14. Global Antivenom Sales Value Market Share by Type, 2024 & 2031

Figure 15. Global Antivenom Sales Volume by Type (2020 VS 2024 VS 2031) & (K Vials)

Figure 16. Global Antivenom Sales Volume Market Share by Type, 2024 & 2031

Figure 17. Global Antivenom Price by Type (2020-2031) & (USD/Vial)

Figure 18. Product Picture of Non-profit Institutions

Figure 19. Product Picture of Hospitals and Clinic

Figure 20. Global Antivenom Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)

Figure 21. Global Antivenom Sales Value Market Share by Application, 2024 & 2031

Figure 22. Global Antivenom Sales Volume by Application (2020 VS 2024 VS 2031) & (K Vials)

Figure 23. Global Antivenom Sales Volume Market Share by Application, 2024 & 2031

Figure 24. Global Antivenom Price by Application (2020-2031) & (USD/Vial)

Figure 25. North America Antivenom Sales Value (2020-2031) & (US$ Million)

Figure 26. North America Antivenom Sales Value by Country (%), 2024 VS 2031

Figure 27. Europe Antivenom Sales Value, (2020-2031) & (US$ Million)

Figure 28. Europe Antivenom Sales Value by Country (%), 2024 VS 2031

Figure 29. Asia Pacific Antivenom Sales Value, (2020-2031) & (US$ Million)

Figure 30. Asia Pacific Antivenom Sales Value by Region (%), 2024 VS 2031

Figure 31. South America Antivenom Sales Value, (2020-2031) & (US$ Million)

Figure 32. South America Antivenom Sales Value by Country (%), 2024 VS 2031

Figure 33. Middle East & Africa Antivenom Sales Value, (2020-2031) & (US$ Million)

Figure 34. Middle East & Africa Antivenom Sales Value by Country (%), 2024 VS 2031

Figure 35. Key Countries/Regions Antivenom Sales Value (%), (2020-2031)

Figure 36. Key Countries/Regions Antivenom Sales Volume (%), (2020-2031)

Figure 37. United States Antivenom Sales Value, (2020-2031) & (US$ Million)

Figure 38. United States Antivenom Sales Value by Type (%), 2024 VS 2031

Figure 39. United States Antivenom Sales Value by Application (%), 2024 VS 2031

Figure 40. Europe Antivenom Sales Value, (2020-2031) & (US$ Million)

Figure 41. Europe Antivenom Sales Value by Type (%), 2024 VS 2031

Figure 42. Europe Antivenom Sales Value by Application (%), 2024 VS 2031

Figure 43. China Antivenom Sales Value, (2020-2031) & (US$ Million)

Figure 44. China Antivenom Sales Value by Type (%), 2024 VS 2031

Figure 45. China Antivenom Sales Value by Application (%), 2024 VS 2031

Figure 46. Japan Antivenom Sales Value, (2020-2031) & (US$ Million)

Figure 47. Japan Antivenom Sales Value by Type (%), 2024 VS 2031

Figure 48. Japan Antivenom Sales Value by Application (%), 2024 VS 2031

Figure 49. South Korea Antivenom Sales Value, (2020-2031) & (US$ Million)

Figure 50. South Korea Antivenom Sales Value by Type (%), 2024 VS 2031

Figure 51. South Korea Antivenom Sales Value by Application (%), 2024 VS 2031

Figure 52. Southeast Asia Antivenom Sales Value, (2020-2031) & (US$ Million)

Figure 53. Southeast Asia Antivenom Sales Value by Type (%), 2024 VS 2031

Figure 54. Southeast Asia Antivenom Sales Value by Application (%), 2024 VS 2031

Figure 55. India Antivenom Sales Value, (2020-2031) & (US$ Million)

Figure 56. India Antivenom Sales Value by Type (%), 2024 VS 2031

Figure 57. India Antivenom Sales Value by Application (%), 2024 VS 2031

Figure 58. Antivenom Industrial Chain

Figure 59. Antivenom Manufacturing Cost Structure

Figure 60. Channels of Distribution (Direct Sales, and Distribution)

Figure 61. Bottom-up and Top-down Approaches for This Report

Figure 62. Data Triangulation

Figure 63. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$3950

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Antivenom Serum Market Research Report 2024

Monovalent Antivenom Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Polyvalent Antivenom Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Antivenoms for Treating Spider Bites Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Antivenin Market Insights Forecast to 2030

Global Venom Antiserum Market Insights Forecast to 2030

Global Snake Antivenom Immunoglobulin Market Research Report 2024

Global Snake Venom Antiserum Market Insights Forecast to 2030

Antivenene Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Antivenom Immunoglobulin Market Research Report 2025

Global Research Grade Antibodies Market Research Report 2024

Global Immunoglobulin G Antibody Therapeutics Market Insights Forecast to 2030

Global His Tag Antibody Market Research Report 2024

Global Antiserum Market Research Report 2025

Global Antitoxin Serum Market Research Report 2024

Global Combination Antibody Therapy Market Research Report 2024

Global DCT Antibody Market Research Report 2024

Antibody Therapeutics and Blood Antibody Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Intravenous Antibodies Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

RELATED REPORTS

Global Pharma and Healthcare Social Media Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-14Y6812

Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Food Additives Testing Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-34O3983

Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Gabapentin API Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-9V17601

Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Electronic Informed Consent Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-22C17047

Fri Sep 12 00:00:00 UTC 2025

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions